A patient is admitted to a hospital for treatment for first-time symptoms of mania and is exhibiting euphoric mania. Which medication will the provider order?

Long-term maintenance therapy in Bipolar disorder focuses on preventing recurrence of mood episodes, particularly depressive relapses which are common and disabling. Maintenance agents are selected based on their ability to stabilize mood over time with a favorable side effect profile. Some medications are more effective for acute mania, while others are better suited for long-term stabilization. Identifying the correct agent is essential for sustained symptom control and improved quality of life.

Rationale:
A. Divalproex sodium is effective for acute manic episodes and is commonly used in patients with rapid cycling or mixed features. While it may be used in maintenance, it is not primarily preferred for long-term prevention of depressive episodes. Its side effect profile, including hepatotoxicity and weight gain, may also limit long-term use in some patients.

B. Olanzapine is useful in acute mania and can be used in maintenance therapy, often in combination with other agents. However, it is associated with significant metabolic side effects such as weight gain, hyperlipidemia, and insulin resistance. These risks make it less favorable as a primary long-term maintenance option compared to other agents.

C. Lamotrigine is particularly effective for long-term maintenance of bipolar disorder, especially in preventing depressive episodes. It works by stabilizing neuronal membranes and modulating glutamate release. Its relatively favorable side effect profile and efficacy in reducing relapse make it a preferred option for maintenance therapy.

D. Carbamazepine is used in acute mania and in some maintenance cases, particularly when patients do not respond to first-line agents. However, it has a higher risk of drug interactions and adverse effects such as bone marrow suppression. These limitations make it less commonly chosen as a primary long-term maintenance medication.

Ergotamine and other ergot-derived antimigraine medications cause vasoconstriction by stimulating serotonin and adrenergic receptors in vascular smooth muscle. Excessive dosing or prolonged use can lead to systemic vasospasm, reducing blood flow to the extremities. This can produce ischemic symptoms such as cold, pale limbs and paresthesia. Recognizing drug-induced vascular complications is essential in patients being treated for migraine disorders.

Rationale:
A. Ergotamine withdrawal is not a recognized clinical syndrome. Unlike dependence-producing substances, ergot derivatives do not cause a classic withdrawal pattern characterized by rebound systemic symptoms. The presentation of cold, pale extremities suggests vasoconstriction rather than withdrawal effects.

B. Severe migraine symptoms typically include unilateral pulsating headache, nausea, photophobia, and phonophobia. While migraines can cause neurologic symptoms such as aura, they do not cause peripheral ischemic signs like cool, pale extremities.

C. Ergotism is caused by excessive exposure to ergot-derived medications such as ergotamine. It results in intense peripheral vasoconstriction leading to ischemia, numbness, cold extremities, and pallor. Severe cases may progress to gangrene if not promptly recognized and treated by discontinuing the offending agent.

D. Sumatriptan side effects typically include transient sensations such as flushing, dizziness, or chest tightness due to vasoconstrictive activity, but it rarely causes severe peripheral ischemia. The symptoms described (cool, pale hands and feet with numbness) are more consistent with prolonged ergot-induced vasospasm rather than triptan adverse effects.